WEBSITE BSE:0 NSE: Inc. Year: 2003 Industry: Hospital & Healthcare Services My Bucket: Add Stock
Last updated: 15:48
No Notes Added Yet
Chandan Healthcare Ltd. is a prominent diagnostic services provider in North India, established in September 2003. Headquartered in Lucknow, Uttar Pradesh, the company operates a comprehensive network of diagnostic facilities, including one flagship laboratory, seven central laboratories, twenty-six satellite centers, and over three hundred collection centers across more than 23 cities in Uttar Pradesh and 19 cities in Uttarakhand. Chandan Healthcare offers a wide array of services encompassing 1,496 tests, such as routine and specialized patho...Read More
Chandan Healthcare Ltd. is a prominent diagnostic services provider in North India, established in September 2003. Headquartered in Lucknow, Uttar Pradesh, the company operates a comprehensive network of diagnostic facilities, including one flagship laboratory, seven central laboratories, twenty-six satellite centers, and over three hundred collection centers across more than 23 cities in Uttar Pradesh and 19 cities in Uttarakhand. Chandan Healthcare offers a wide array of services encompassing 1,496 tests, such as routine and specialized pathology tests, as well as radiology services like X-rays, ultrasounds, CT scans, and MRIs. The company employs a team of 15 radiologists, 23 pathologists, and over 161 other qualified professionals to ensure high-quality service delivery .​ In addition to diagnostic services, Chandan Healthcare operates a subsidiary, Chandan Pharmacy Limited, which runs 31 medical stores offering pharmaceutical products, FMCG items, and surgical supplies . The company\'s business model focuses on a cluster and collection points approach, facilitating efficient sample collection and testing processes. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹615 Cr.
Stock P/E 26.2
P/B 4.8
Current Price ₹251.7
Book Value ₹ 52.2
Face Value 10
52W High ₹358
Dividend Yield 0%
52W Low ₹ 150.3
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Dec 2024 | Dec 2025 |
|---|---|---|
| Net Sales | 55 | 65 |
| Other Income | 0 | 1 |
| Total Income | 55 | 66 |
| Total Expenditure | 46 | 53 |
| Operating Profit | 9 | 13 |
| Interest | 1 | 1 |
| Depreciation | 1 | 2 |
| Exceptional Income / Expenses | 0 | -2 |
| Profit Before Tax | 7 | 7 |
| Provision for Tax | 2 | 2 |
| Profit After Tax | 5 | 5 |
| Adjustments | -0 | -0 |
| Profit After Adjustments | 4 | 5 |
| Adjusted Earnings Per Share | 2.1 | 1.9 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 120 | 137 | 177 | 230 | 120 |
| Other Income | 0 | 0 | 1 | 2 | 1 |
| Total Income | 120 | 137 | 178 | 232 | 121 |
| Total Expenditure | 117 | 128 | 150 | 189 | 99 |
| Operating Profit | 3 | 10 | 28 | 43 | 22 |
| Interest | 2 | 2 | 3 | 5 | 2 |
| Depreciation | 2 | 2 | 3 | 7 | 3 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -2 |
| Profit Before Tax | -1 | 5 | 21 | 32 | 14 |
| Provision for Tax | 0 | 1 | 5 | 9 | 4 |
| Profit After Tax | -1 | 4 | 16 | 24 | 10 |
| Adjustments | -2 | -0 | -0 | -1 | 0 |
| Profit After Adjustments | -3 | 3 | 16 | 22 | 9 |
| Adjusted Earnings Per Share | -1.6 | 1.7 | 8.1 | 9.1 | 4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 30% | 24% | 0% | 0% |
| Operating Profit CAGR | 54% | 143% | 0% | 0% |
| PAT CAGR | 50% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 37% | NA% | NA% | NA% |
| ROE Average | 29% | 30% | 21% | 21% |
| ROCE Average | 30% | 28% | 22% | 22% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 24 | 27 | 41 | 123 |
| Minority's Interest | 3 | 3 | 2 | 4 |
| Borrowings | 7 | 8 | 12 | 22 |
| Other Non-Current Liabilities | 3 | 4 | 4 | 5 |
| Total Current Liabilities | 45 | 57 | 58 | 57 |
| Total Liabilities | 82 | 98 | 118 | 211 |
| Fixed Assets | 29 | 33 | 48 | 76 |
| Other Non-Current Assets | 9 | 12 | 8 | 24 |
| Total Current Assets | 43 | 54 | 61 | 110 |
| Total Assets | 82 | 98 | 118 | 211 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 3 | 2 | 2 | 4 |
| Cash Flow from Operating Activities | 6 | 4 | 1 | -29 |
| Cash Flow from Investing Activities | -11 | -6 | -15 | -36 |
| Cash Flow from Financing Activities | 3 | 2 | 16 | 67 |
| Net Cash Inflow / Outflow | -1 | 0 | 2 | 2 |
| Closing Cash & Cash Equivalent | 2 | 2 | 4 | 6 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | -1.59 | 1.68 | 8.14 | 9.07 |
| CEPS(Rs) | 0.43 | 2.84 | 9.88 | 12.38 |
| DPS(Rs) | 0.5 | 1 | 1.5 | 0 |
| Book NAV/Share(Rs) | 11.97 | 13.65 | 20.58 | 50.14 |
| Core EBITDA Margin(%) | 1.89 | 6.85 | 14.95 | 17.96 |
| EBIT Margin(%) | 0.54 | 5.43 | 13.71 | 15.92 |
| Pre Tax Margin(%) | -0.89 | 3.66 | 12.15 | 13.93 |
| PAT Margin (%) | -0.91 | 2.62 | 9.26 | 10.22 |
| Cash Profit Margin (%) | 0.73 | 4.15 | 11.19 | 13.15 |
| ROA(%) | -1.34 | 3.99 | 15.13 | 14.31 |
| ROE(%) | -4.57 | 14 | 47.78 | 28.72 |
| ROCE(%) | 1.59 | 16.67 | 38.52 | 29.57 |
| Receivable days | 87.61 | 69.84 | 54.05 | 59.72 |
| Inventory Days | 20.03 | 21.91 | 29.06 | 39.35 |
| Payable days | 184.62 | 220.93 | 142.42 | 89.69 |
| PER(x) | 0 | 0 | 0 | 19.96 |
| Price/Book(x) | 0 | 0 | 0 | 3.61 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.29 | 0.29 | 0.29 | 2.11 |
| EV/Core EBITDA(x) | 13.43 | 4.13 | 1.88 | 11.17 |
| Net Sales Growth(%) | 0 | 14.49 | 29 | 30.31 |
| EBIT Growth(%) | 0 | 1050.2 | 225.87 | 51.32 |
| PAT Growth(%) | 0 | 428.27 | 356.06 | 43.77 |
| EPS Growth(%) | 0 | 206.07 | 383.27 | 11.41 |
| Debt/Equity(x) | 0.69 | 0.78 | 0.87 | 0.39 |
| Current Ratio(x) | 0.96 | 0.95 | 1.06 | 1.94 |
| Quick Ratio(x) | 0.81 | 0.77 | 0.75 | 1.39 |
| Interest Cover(x) | 0.38 | 3.07 | 8.8 | 8.01 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0.11 |
| # | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 49.43 | 49.47 | 49.47 | 49.55 |
| FII | 3.86 | 1.11 | 0 | 0.01 |
| DII | 6.7 | 5.02 | 4.76 | 5.03 |
| Public | 40 | 44.41 | 45.78 | 45.42 |
| Others | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 |
| # | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 1.21 | 1.21 | 1.21 | 1.21 |
| FII | 0.09 | 0.03 | 0 | 0 |
| DII | 0.16 | 0.12 | 0.12 | 0.12 |
| Public | 0.98 | 1.09 | 1.12 | 1.11 |
| Others | 0 | 0 | 0 | 0 |
| Total | 2.45 | 2.45 | 2.45 | 2.45 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
